REFERENCES
- Coutinho, A. D., and Trindade Barretto, F. (1969). Treatment of hepatosplenic schistosomiasis mansoni with niridazole: relationships among liver function, effective dose, and side effects. Arm. N.Y. Acad. Sci., 160, 612.
- Faigle, J. W., Blair, D. M., Clarke, V. de V., Davidson, L. A. G., Dukes, D. C., and Keberle, H. (1970). The metabolism of niridazole (AmbilharR) in man. I. Investigations on patients suffering from clinically mild forms of Schistosoma haematobium and Schistosoma mansoni infection. Ann. trop. Med. Parasit., 64, 373.
- Faigle, J. W., Blair, D. M., Clarke, V. de V., Davidson, L. A. G., Dukes, D. C., and Keberle, H. (1966). The metabolic fate of CIBA 32,644-Ba. Acta trop., 9, Suppl., 8.
- Faigle, J. W., Blair, D. M., Clarke, V. de V., Davidson, L. A. G., Dukes, D. C., and Keberle, H. (1969). Metabolism of niridazole in various species including man. Ann. N.Y. Acad. Sci., 160, 544.
- Fontanilles, F. (1969). Risks versus benefits in antischistosomal therapy. Ann. N. Y. Acad. Sci., 160, 811.
- Lambert, C. R. (1966). Nouveau traitement des schistosomiases et de l'amibiase, le CIBA 32,644-Ba. Acta trop., 23, 1.
- Martins Da Rocha, R., and Gil, F. B. (1966). Essais préliminaires sur l'élimination du CIBA 32,644-Bamarqué C14. Acta trop., 9, Suppl., 23.